Show simple item record

dc.contributor.authorKerkmeijer, LGW
dc.contributor.authorFuller, CD
dc.contributor.authorVerkooijen, HM
dc.contributor.authorVerheij, M
dc.contributor.authorChoudhury, A
dc.contributor.authorHarrington, KJ
dc.contributor.authorSchultz, C
dc.contributor.authorSahgal, A
dc.contributor.authorFrank, SJ
dc.contributor.authorGoldwein, J
dc.contributor.authorBrown, KJ
dc.contributor.authorMinsky, BD
dc.contributor.authorvan Vulpen, M
dc.contributor.authorMR-Linac Consortium Clinical Steering Committee
dc.date.accessioned2017-09-06T10:53:58Z
dc.date.accessioned2017-09-07T15:24:56Z
dc.date.issued2016-01
dc.identifier.citationFrontiers in oncology, 2016, 6 pp. 215 - ?
dc.identifier.issn2234-943X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/815
dc.identifier.eissn2234-943X
dc.identifier.doi10.3389/fonc.2016.00215
dc.description.abstractAn international research consortium has been formed to facilitate evidence-based introduction of MR-guided radiotherapy (MR-linac) and to address how the MR-linac could be used to achieve an optimized radiation treatment approach to improve patients' survival, local, and regional tumor control and quality of life. The present paper describes the organizational structure of the clinical part of the MR-linac consortium. Furthermore, it elucidates why collaboration on this large project is necessary, and how a central data registry program will be implemented.
dc.formatElectronic-eCollection
dc.format.extent215 - ?
dc.languageeng
dc.language.isoeng
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/812
dc.relation.replacesinternal/812
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectMR-Linac Consortium Clinical Steering Committee
dc.titleThe MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development.
dc.typeJournal Article
dcterms.dateAccepted2016-09-28
rioxxterms.versionofrecord10.3389/fonc.2016.00215
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFrontiers in oncology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume6
pubs.embargo.termsNot known
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0